Tag Archive for: GSK

Curve Therapeutics continues to enhance leadership team with appointment of Rab Prinjha as Chief R&D Officer

/in

Deep expertise in leading drug discovery programs across oncology, neuroscience and epigenetics Will drive advancement of Curve’s rich pipeline of first-in-class therapeutic assets Builds on recent leadership team appointments, including Andre Hoekema as Chair of the Board Southampton, UK, 9 October 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a […]

Read more

Asceneuron Secures $100 Million Series C Financing to Advance Groundbreaking Therapeutics in Neurodegenerative Diseases

/in

Financing led by Novo Holdings, including new investment from EQT Life Sciences – LSP Dementia Fund, OrbiMed and SR One with participation from existing investors M Ventures, Sofinnova Partners, GSK Equities Investments Limited and Johnson & Johnson Innovation – JJDC, Inc. Funds will be used to progress lead asset ASN51, an oral small molecule OGA […]

Read more

iOnctura announces expansion of roginolisib clinical trial program to NSCLC

/in

• Phase II study in non-small-cell-lung-cancer (NSCLC) to be run in collaboration with the ETOP IBCSG Partners Foundation across sites in Europe • Study will investigate dostarlimab + roginolisib +/- docetaxel in patients with NSCLC resistant to first-line checkpoint inhibitor therapy Geneva, Switzerland and Amsterdam, The Netherlands, 9 July 2024 – iOnctura, a clinical-stage biopharmaceutical […]

Read more